Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425279 · ClinicalTrials.gov registry record · Phase 1
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
A Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, sponsored by BioAtla.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT03425279: Completed Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, sponsored by BioAtla.
NCT03425279 is a Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma that has completed, run by BioAtla. The registered enrollment target is 245 participants, above the 66-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (271% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03425279, a Phase 1 study of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
Primary Outcome
Assess dose limiting toxicity as defined in the protocol
Conditions Studied
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-AXL-ADC
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- USC Norris Comprehensive Cancer Center - Los Angeles
- Tower Hematology Oncology Medical Group - Los Angeles
- Precision NextGen Oncology - Los Angeles
- UCSF Medical Center - Cancer Immunotherapy Clinic (CIC) - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Columbia University - New York
- Memorial Sloan Kettering - New York
Colorado
- University of Colorado - Aurora
- Sarah Cannon Research Institute at Health One - Denver
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- The University of Arizona Cancer Center - Tucson
District of Columbia
- Children's Research Institute - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 1 |
What the finished NCT03425279 record still lists
NCT03425279 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 5 other Undifferentiated Pleomorphic Sarcoma trials with a reported enrollment target (271% higher).
The record links to 2 conditions, with Undifferentiated Pleomorphic Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT03425279 names 20 study sites across 12 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT03425279 about?
NCT03425279 is a clinical study titled "CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma". The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
What is the current status of trial NCT03425279?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2018-02-15. Estimated completion is 2025-01-08.
What conditions does trial NCT03425279 study?
This clinical trial studies the following conditions: Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma.
What interventions are being tested in trial NCT03425279?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-AXL-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03425279?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03425279 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Undifferentiated Pleomorphic Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
RECRUITING · NA
-
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
RECRUITING · Phase 2
-
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
ACTIVE NOT RECRUITING · Phase 2
-
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI